



ASX ANNOUNCEMENT

Lumos Diagnostics Quarterly Activity Statement, Cash Flow and FebriDx® Commercial Update

Key Highlights from the First Quarter of Financial Year 2027

- **U.S. commercialisation of FebriDx® as of 11 October 2026** - 265 healthcare sites across 29 states actively ordering and using FebriDx®, up from 215 sites / 26 states on 15 September 2026¹ and 170 sites / 24 states on 26 July 2026. Evaluations are underway across 485 sites, up from 405 sites on 15 September 2026
- **Q1 FY27 total revenue of US\$2.0 million** - product revenue up 224% and FebriDx® sales up 351%, excluding the one-time PHASE exclusivity fee, in the pc.
- **13 top 100 Urgent Care Groups now in evaluation stage or with live FebriDx® sites**
 - Three additional top 100 urgent care organizations, representing over 120 sites nationally, are now progressing clinical and economic validation across 50 sites. The number of Acute Respiratory Infection (ARI) patients treated in these 50 sites is estimated to be 250,000 annually
 - One new health system, focused on primary care with 12+ locations and 300 primary care providers located in the Northeast U.S., has committed to deploying FebriDx® across all sites immediately. This system is expected to treat over 50,000 ARI patients annually
- **FebriDx® paediatric study** - approx. 400 patients have been enrolled to date. Total enrollment and bacterial positive cases has been lower than expected in the study plan. Three hospital emergency departments are being added in Q2 FY27 to help address this. In addition, Lumos and BARDA are working closely to monitor the study's progress including engaging with the FDA to see whether the study parameters can be adjusted to address the bacterial-positive presentation rate encountered to date.
- **Debt-free, with cash of US\$11.8 million** at 30 September 2026
- **Operating cash outflow** of US\$4.7 million, including US\$1.0 million investment in inventory ahead of the U.S. 2026/27 respiratory season, facility upgrades, sales and marketing spend, and undertaking the paediatric study.

All amounts are in USD, the Company's reporting currency, unless otherwise stated.

¹ Last ASX FebriDx® commercialisation update.

MELBOURNE, Australia (27 October 2026) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care diagnostic technologies, is pleased to release its Quarterly Activity Statement, Appendix 4C Quarterly Cash Flow Report and FebriDx® commercial update for the first quarter of FY27 (Q1 FY27 / the three months ended 30 September 2026).

Operational Update

Revenue Summary:

US\$000	Quarter 1			FY27 YTD (3 months)		
	FY27	FY26	Mv't	FY27	FY26	Mv't
Products	564	174	+224%	564	174	+224%
Products – Exclusivity Fee	-	1,000	n.m.	-	1,000	n/m
Services	1,478	2,189	-32%	1,478	2,189	-32%
Total	2,042	3,363	-39%	2,042	3,363	-39%

Quarter 1 - FY27 Review

Lumos recorded unaudited revenue of US\$2.0 million for the quarter ended 30 September 2026, down 39% on the pcq.

The Products business generated operating revenue of US\$0.6 million for the quarter, compared with US\$0.2 million in the pcq, an increase of 224%. FebriDx® product revenue increased 351% on the pcq. Sales from the third-party supplied CorDx Flu A/B/COVID combo test and the Binx point-of-care STI testing kits, whilst remaining small, both grew by 13% and 155%, respectively.

The previous corresponding quarter also included a US\$1.0 million exclusivity fee from PHASE Scientific (“PHASE”) that was a one-time payment.

The Services business generated revenue of US\$1.5 million, a decrease of 32% on the pcq. Revenue was impacted negatively by US\$0.5 million from the lower amortisation rate on the Hologic IP licence fee (US\$0.1 million recognised in Q1 FY27 v’s US\$0.6 million in Q1 FY26), following the extension of fFN project timeline. Excluding the amortisation of the licence fee, services revenue was US\$1.4 million, compared with US\$1.6 million in the pcq. Development work continued on 12 projects throughout the quarter.

Products Division

We provide the following product updates below:

FebriDx®

FebriDx® is Lumos’ unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. To date, Lumos has received regulatory registrations for the use of FebriDx® in the U.S., UK, Europe, Kuwait, UAE and Australia.

The U.S. FDA’s granting of a CLIA waiver for FebriDx on 27 March 2026 marked a transformative milestone for the Company. The CLIA waiver expands the addressable market for FebriDx® by approximately 15-fold,

extending its availability to over 300,000 locations across the U.S.². This significantly broadens access to over 80 million U.S. patients presenting with acute respiratory infections per annum and unlocks a total market opportunity exceeding US\$1.0 billion. The waiver enables product adoption across a wide range of healthcare settings holding a Certificate of Waiver, including primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres.

Lumos has an exclusive distribution agreement for the U.S. market for FebriDx® with PHASE Scientific (PHASE) valued at US\$317 million over 6 years (ASX: 16 July 2025). Under this agreement, the granting of CLIA waiver triggered an immediate payment of US\$5.0 million from PHASE, which was received on 14 April 2026. Additionally, on 7 May 2026 Lumos received a US\$0.5 million milestone payment under its contract with BARDA for achieving CLIA waiver.

U.S. FebriDx® Commercialisation Update

The expanded market opportunity referred to above is closely aligned with Lumos' U.S. commercialisation strategy, which is focused on accelerating adoption through targeted healthcare provider education, integration of FebriDx® into clinical workflows, and the expansion of reimbursement coverage from private payors.

These initiatives are being supported through the Company's strategic partnerships with PHASE, PRO-spectus, AcuityMD, and CG Life.

Lumos continues to utilise a four-stage commercial framework to help track and communicate how accounts are advancing. This framework provides investors with a clear way to understand how priority accounts progress from initial engagement through to scaled, protocol-driven use of FebriDx®:

- **Qualified opportunities** - priority accounts identified and engaged based on patient volume, payer mix, strategic fit and network scale.
- **Evaluation Phase: Clinical and economic validation** - targeted clinical performance, reimbursement, workflow and health-economic assessment activities conducted across one or more sites to support broader adoption decisions.
- **Implementation Phase I: Network rollout** - deployment across multiple sites within an account following successful validation of clinical utility, operational fit and reimbursement readiness.
- **Implementation Phase II: Standardised adoption** - FebriDx® becomes embedded in standing orders, triage protocols or routine clinical pathways, supporting repeat ordering and scaled utilisation across the account.

Lumos' initial commercial focus is on Tier 1 and Tier 2 customers, comprising the top 100 Urgent Care operators in the U.S., representing approximately 40% of U.S. urgent care clinics, and totaling more than 5,700 clinical sites nationwide.

As of 11 October 2026, 265 urgent care sites (up 50 sites / +23% since 15 September 2026) across 29 states (up 3 states) are live, in either the rollout stage or having implemented a standardised adoption of FebriDx®. This includes 5 of the top 100 US urgent care groups.

² Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database).

In addition, 485 healthcare sites (up 80 sites / +20% since 15 September 2026) are in the evaluation phase, conducting clinical and economic validation of FebriDx®. This includes 8 of the top 100 U.S. urgent care groups.

	IN EVALUATION Clinical & economic validation underway			
POST QUALIFICATION PIPELINE PHASES	Sites in active evaluation	Estimated ARI visits per annum ¹	Top 100 Urgent Care Groups	
Evaluation Phases: ³ Clinical & Economic Validation	485	1.9m–2.7m	8 in Top 100	
	LIVE & SCALING Network rollout in market			
	Live sites	States covered	Estimated ARI visits per annum ¹	Top 100 Urgent Care Groups
Implementation Phases: Phase I: Network Rollout Phase 2: Standardised Adoption	265	29	1.1m-1.5m	5 in Top 100
	An increase of 50 live sites and 3 states; and up 80 evaluation sites since 15 September 2026. The 265 live sites is the total for Implementation Phases. Phase I and Phase II are labels within that total, not additive rows. Payment coverage at US\$41.38/test: >90% ²			

¹Average ARI (acute respiratory illness) visits per US urgent care site: ~4,000–5,500 per year (~12–17 per day) Derived from: UCA average visit volume of ~34 patients/day/site (2025), annualized to ~12,400 visits/site/year, multiplied by respiratory-related illness share of ~35%–40% of urgent care visits (the single largest visit category).Sources: Urgent Care Association, Urgent Care Data (2025); Health Care Cost Institute, "Respiratory-Related Illness is the Top Reason People Use Urgent Care" (analysis of 73M commercial urgent care visits, 2018–2022).

²As reported as at 27 July 2026. Reimbursement coverage data will be provided at a frequency determined by formal reporting from Acuity MD.

³Metrics in the table above for the Evaluation Phases only include sites under active engagement (i.e. performing clinical & economic validation). Qualified Opportunities, are in addition to these metrics, and include a significant number of sites identified by Lumos and its partners as potential FebriDx customers, including accounts outside the Top 100.

Since the September update, a top 100 urgent care group and leading academic health system in the Midwest, has moved to standardised adoption within their 20+ outpatient settings after successfully training all providers in September. The entire network, focused on growth in the outpatient setting, currently encompasses over 100 locations, with in excess of 2.5 million outpatient visits annually across within the entire network.

In addition, 3 top 100 U.S. urgent care groups representing over 120 urgent care sites, have committed to evaluating FebriDx® across a combined total of 50 sites. Around 250,000 ARI patients are estimated to be treated in these 50 sites.

Further details on these 3 top 100 urgent care groups are as follows:

- Group #1 is part of a nonprofit health system with 25+ hospital locations and over 400 locations in the Southern U.S. The urgent care opportunity represents 30+ urgent care clinics, treating approximately 400,000 ARI patients annually.

- Group #2 is part of an integrated health system with more than 65,000 caregivers, treating more than 5.0 million patient visits per year at over 170 locations. The urgent care opportunity encompasses over 30 clinics in the Midwest, expected to treat over 150,000 ARI patients annually.
- Group #3 is a large physician-led multi-specialty group with more than 500 providers across 50+ high volume locations in metropolitan areas of the Northeast U.S. ARI visits are estimated at 300,000 annually.

In addition to the top 100 urgent care strategy, primary care demand continues to build. A health network located in the U.S. Northeast and focused on primary care with 12+ locations and more than 300 primary care providers has committed to immediate, full deployment of FebriDx® at all locations. The number of ARI visits is estimated at over 50,000 annually.

Validation activities across these accounts include assessment of clinical performance, reimbursement, workflow integration and health-economic impact, which will inform decisions on broader deployment.

These deployments continue to validate Lumos' strategy of partnering with scaled urgent care providers and integrated health systems, where FebriDx® can be embedded into frontline clinical pathways for patients presenting symptoms of acute respiratory infection. In these settings, FebriDx® has the potential to support more informed prescribing decisions, antimicrobial stewardship initiatives, patient flow efficiency and appropriate referral or escalation pathways.

Consistency with prior market communication:

This announcement is intended to provide information for the FebriDx® commercial pipeline that is consistent with the Company's previously disclosed commercial metrics. Lumos will continue to report progress in a consistent manner as published in the investor presentation released on 27 July 2026, including site growth, geographic expansion and the use of average ARI visits per site as a benchmark for the potential ARI-related commercial opportunity.

At the same time, the Company expects to continue refining how it communicates account maturity by expanding the dashboard associated with qualified opportunities, clinical and economic validation, network rollout and standardised adoption phases, so investors can better assess how individual priority accounts are evolving over time.

All FebriDx® sales in the U.S. are made through Lumos' exclusive distribution partner, PHASE, as disclosed to the ASX on 16 July 2025, and Lumos recognises FebriDx® revenue when product is shipped from Lumos to Phase.

Through the U.S. respiratory season, Lumos is working with PHASE, PRO-spectus, AcuityMD and CG Life on provider education, reimbursement support and account activation.

CLIA waived paediatric study continues: The study commenced on 22 October 2025 and was expected to run until end CY2026 to reach its statistical endpoint. Enrollment has continued, with approx. 400 patients now enrolled, up from 250 at Milestone 7 in May 2026. During Q2 FY27, three hospital emergency departments will be added to increase total enrollment and bacterial-positive cases.

Lumos, together with BARDA, will discuss the study with the FDA by end of the calendar year 2026, including whether adjustments to the study parameters could allow the endpoint to be reached on a revised basis. To-date, no change has been agreed.

Lumos will update the market after that discussion, if any change is made to the study design or timetable. Cumulative BARDA receipts remain US\$2.6 million of up to US\$6.2 million. No further milestone was triggered in the first quarter of FY27. Current U.S. commercialisation of FebriDx®, including CLIA waiver for patients aged 12 to 64 years, is unaffected. A potential market expansion of 15% - 20% in the U.S. is estimated if the paediatric indication is achieved.

Development Services and Contract Manufacturing Division

Lumos generates revenue from the provision of point-of-care diagnostic test and custom reader development services, contract manufacturing and IP license revenue. Development services included ongoing work on 12 projects during the quarter, including projects for Hologic, Micro-Pak, TeleMedVet and Aptatek Biosciences.

Hologic -fFN Diagnostic Product

On 11 January 2024, Lumos announced an IP licensing agreement (worth US\$10.0 million, with payment received in FY24) and a Development Agreement (initially worth US\$4.7 million) with Hologic, a leading global women's health provider, to develop the next generation of Hologic's on market fFN diagnostic product for pre-term birth, for which Hologic is the only global manufacturer. A key focus of the development program is to adapt the test for use on the Lumos proprietary reader platform and provide improved connectivity options.

The development project has since been expanded by six additional scopes of work (SOW). A breakdown of the expanded SOW's is as follows:

1. March 2025 for between US\$0.6 - US\$0.8 million (relating to the delivery of the system prototype in Phase 3)
2. August 2025 for between US\$0.7 - US\$0.9 million (relating to the assay feasibility work in Phase 2)
3. November 2025 for between US\$0.5 - US\$0.6 million (relating to assay feasibility work in Phase 2)
4. February 2026 for US\$0.2 million (relating to hardware works in Phase 3);
5. March 2026 for US\$0.3 million (relating to software works in Phase 3); and
6. May 2026 for US\$0.1 million (relating to hardware works in Phase 3).

During the first quarter, work was successfully completed by Lumos on SOW's number 4, 5 and 6., The outputs of these SOW's have been used to refine the Phase 3 reader plan, resulting in further expansion of work from the original Development Agreement. Lumos has provided a proposal, as requested by Hologic, for the additional reader work. As of the date of this announcement, the Company is anticipating a response on the proposal shortly.

Including the six additional SOW's, the body of work under the Development Agreement is being conducted across three phases (which include the nine original milestones), providing total milestone payments of between US\$7.0 - US\$7.7 million, structured as follows:

- Phase 1 (milestone 1) - Product Definition and Planning: define the parameters for the product and establish a project plan - US\$0.4 million – this phase has been completed, and payment has been received;
- Phase 2 (milestones 2 and 3) - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarkers - US\$3.0 to US\$3.3 million – work on milestone 2 and 3 and the two additional SOW's have been completed. For this phase, payments of US\$3.3 million have been received to-date.
- Phase 3 (milestones 4 to 9) - System Prototype Delivery: deliver a working prototype of the system – US\$3.6 - US\$4.0 million – milestone 4 and 5 of this phase are in progress. The four additional SOW's have been completed with the outputs expected to further expand the program of work for milestones 4 to 9. Due to the additional SOW's on assay feasibility and the hardware, work on the initial phase 3 milestones has been delayed, so the estimated timeline for the project has been pushed out to around June 2028. For this phase, payments of US\$1.8 million have been received to-date.

Summary of Cash Receipts and Outflows

Cash Flow Summary:

US\$000	Quarter 1 (FY27 – 3 months)	FY27 YTD (3 months)
Opening cash	15,429	15,429
Operating cash flow:		
Receipts from customers	1,477	1,477
Payments to suppliers and employees	(6,101)	(6,101)
Net finance costs	(80)	(80)
Government grants and tax incentives	-	-
Net cash from / (used in) operating activities	(4,704)	(4,704)
Net cash from / (used in) investing activities	(134)	(134)
Net cash from / (used in) financing activities	1,014	1,014
Net increase / (decrease) in cash	(3,824)	(3,824)
Effect of movement in exchange rates on cash held	186	186
Closing cash	11,791	11,791

Lumos generated cash receipts from customers of US\$1.5 million for the quarter ended 30 September 2026. These receipts are not comparable with the US\$7.0 million in Q4 FY26, which included the US\$5.0 million PHASE prepayment received on 14 April 2026. Current PHASE shipments are being offset against that prepayment, and are therefore recognised as revenue without a corresponding cash receipt. Product revenue was up 224%, and FebriDx® live sites increased during the quarter, which is a better indication of expected demand.

Payments to suppliers and employees for Q1 FY27 were US\$6.1 million, an increase of US\$0.8 million over the Q1 FY26 payments of \$5.3 million. The increase reflects an investment in inventory of US\$1.0 million, ahead of the U.S. respiratory season, sales and marketing spend, and undertaking the paediatric study.

As no BARDA milestone was triggered for the paediatric study, there were no cash receipts from government grants in the quarter. Q4 FY26 included US\$1.7 million of government grants and tax incentives, of which US\$1.2 million was BARDA related paediatric-study payments and US\$0.5 million related to the Australian R&D tax incentive. Cumulative paediatric BARDA receipts to-date remain at US\$2.6 million of up to US\$6.2 million over the life of the study.

In total, the net operating cash outflow for Q1 FY27 was US\$4.7 million.

As advised at the time of the capital raise in March 2026, Lumos is undertaking building works to expand manufacturing capacity at its Carlsbad facility. During Q1 FY27, the work continued on the facility with capital expenditure of US\$0.1 million with the remaining \$0.4 million estimated to be spent as works complete by 31 December 2026.

After including investing and financing activities, net cash outflow for the quarter totaled US\$3.8 million, bringing the cash balance at the end of Q1 FY27, to US\$11.8 million. The Company has no debt.

Payments to Related Entities

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of Appendix 4C, the Company discloses payments of US\$232,000, comprising directors' fees and superannuation for Sam Lanyon, Catherine Robson, Bronwyn Le Grice, directors' fees for Larry Mehren, who retired from the Board post quarter (paid to his related entity, RBLM Consulting), consulting fees for Sam Lanyon, and salary, bonus, medical insurance and 401K retirement payments for Doug Ward. Mr Ward does not receive any additional fees for being a director.

The consulting fees for Sam Lanyon are for ongoing advisory services (ASX: 28 September 2023) whereby Mr Lanyon receives A\$80,000 per annum, inclusive of superannuation, for these services.

Key Priorities

In the year ahead, Lumos will prioritise continued growth in the U.S. market by driving sales of FebriDx® through the implementation of its agreement with PHASE. Key initiatives are aimed at strengthening FebriDx®'s position as a valuable point-of-care diagnostic tool within the U.S. healthcare system.

Key focus areas to drive sales of FebriDx® in the U.S. include:

- **Building market awareness** – Execute the marketing plan to drive awareness and the size of the pipeline
- **Convert the pipeline** - Move the 485 sites in evaluation phase to live status, prioritising the top 100 urgent care groups
- **Drive utilisation** – Implement the “FebriDx-first” protocol so tests per site per month compound across live networks
- **Broaden payer coverage** - Progress formal coverage policies and expand private payer coverage beyond Medicare adoption
- **Add new manufacturing capacity** - Complete and validate the new Carlsbad facility, lifting capacity toward 10 million tests a year

- **Expand clinical opportunity** - Progress the BARDA-funded paediatric study (ages 2–12) to support a future FDA submission, which would expand the U.S. addressable market for FebriDx® by an estimated 15% to 20%

In closing, CEO Doug Ward said: *“The strong commercial momentum achieved since securing CLIA waiver for FebriDx®, continues to exceed our expectations, with 265 live sites using FebriDx®, and a further 485 sites in the evaluation phase. There are now 13 of the top 100 urgent care groups in the U.S. in either evaluation or with live sites. As we prepare for the upcoming respiratory season, these results reinforce the value of FebriDx® for providers, payers and patients, while highlighting the significant growth opportunity ahead of us. Importantly, we continue to establish the key building blocks and commercial framework required to scale adoption and capitalise on that opportunity over the long term”.*

Webinar Invitation

The Company invites investors and analysts to attend its Q1 FY27 results webinar, to be held online on Tuesday, 27 October 2026 at 11.00am (AEDT.)

Participants can register ahead of time, via the following link:

https://us02web.zoom.us/webinar/register/WN_1ImXEdmvShqthL1UxNllw

Once the registration form is complete, investors will receive a confirmation email with details on how to access the meeting. The Lumos team looks forward to welcoming all those who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact: Haley Chartres – Australia HACK Director haley@hck.digital +61 423 139 163	Investor Contact: George Kopsiaftis IR Specialist, IR Department ir@lumosdiagnostics.com +61 409 392 687	Company Registered Office: Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 info@lumosdiagnostics.com +61 3 9087 1598
---	--	--

Appendix 4C

Quarterly Cash Flow report for entities subject to Listing Rule 4.7B

Name of entity

Lumos Diagnostics Holding Limited

ABN

66 630 476 970

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter US\$'000	Year to date (3 months) US\$'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,477	1,477
1.2 Payments for		
(a) service delivery, research and development	(1,058)	(1,058)
(b) product manufacturing and operating costs	(1,821)	(1,821)
(c) sales, advertising and marketing	(773)	(773)
(d) medical affairs and clinical trial costs	(698)	(698)
(e) leased assets	-	-
(f) staff costs*	(866)	(866)
(g) administration and corporate costs	(885)	(885)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	32	32
1.5 Interest and other costs of finance paid	(112)	(112)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(4,704)	(4,704)

*Staff costs have been allocated to their respective departments above.

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(134)	(134)
(d) investments	-	-

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (3 months) US\$'000
	(e) intellectual property	-	-
	(f) other non-current assets (including capitalised product development costs)	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(134)	(134)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	1,318	1,318
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(24)	(24)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other:		
	Lease payments (principal component)	(280)	(280)
3.10	Net cash from / (used in) financing activities	1,014	1,014

Consolidated statement of cash flows		Current quarter US\$'000	Year to date (3 months) US\$'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	15,429	15,429
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,704)	(4,704)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(134)	(134)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,014	1,014
4.5	Effect of movement in exchange rates on cash held	186	186
4.6	Cash and cash equivalents at end of period	11,791	11,791

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US\$'000	Previous quarter US\$'000
5.1	Bank balances	11,791	15,429
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,791	15,429

6.	Payments to related parties of the entity and their associates	Current quarter US\$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	232
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end US\$'000	Amount drawn at quarter end US\$'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	US\$'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(4,704)
8.2 Cash and cash equivalents at quarter end (item 4.6)	11,791
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	11,791
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 October 2026

Authorised by: The Lumos Disclosure Committee
(Name of body or officer authorising release – see note 4)

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.